Advertisement
American Journal of Kidney Diseases

Membranous Nephropathy: A Journey From Bench to Bedside

Published:April 13, 2016DOI:https://doi.org/10.1053/j.ajkd.2016.01.030
      Lessons from an animal model that faithfully resembles human membranous nephropathy (MN) have informed our understanding of the pathogenesis of this organ-specific autoimmune disease and common cause of nephrotic syndrome. After it was established that the subepithelial immune deposits that characterize experimental MN form in situ when circulating antibodies bind to an intrinsic podocyte antigen, it was merely a matter of time before the human antigen was identified. The M-type phospholipase A2 receptor 1 (PLA2R) represents the major target antigen in primary MN, and thrombospondin type 1 domain-containing 7A (THSD7A) was more recently identified as a minor antigen. Serologic tests for anti-PLA2R and kidney biopsy specimen staining for PLA2R show >90% specificity and 70% to 80% sensitivity for the diagnosis of primary MN in most populations. The assays distinguish most cases of primary MN from MN associated with other systemic diseases, and sequential anti-PLA2R titers are useful to monitor treatment response. A positive pretransplantation test result for anti-PLA2R is also helpful for predicting the risk for posttransplantation recurrence. Identification of target epitopes within PLA2R and the genetic association of primary MN with class II major histocompatibility and PLA2R1 variants are 2 additional examples of our evolving understanding of this disease.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Couser W.G.
        • Steinmuller D.R.
        • Stilmant M.M.
        • Salant D.J.
        • Lowenstein L.M.
        Experimental glomerulonephritis in the isolated perfused rat kidney.
        J Clin Invest. 1978; 62: 1275-1287
        • Van Damme B.J.
        • Fleuren G.J.
        • Bakker W.W.
        • Vernier R.L.
        • Hoedemaeker P.J.
        Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. V. Fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis.
        Lab Invest. 1978; 38: 502-510
        • Couser W.G.
        • Salant D.J.
        In situ immune complex formation and glomerular injury.
        Kidney Int. 1980; 17: 1-13
        • Makker S.P.
        • Singh A.K.
        Characterization of the antigen (gp600) of Heymann nephritis.
        Lab Invest. 1984; 50: 287-293
        • Raychowdhury R.
        • Nile J.L.
        • McCluskey R.T.
        • Smith J.A.
        Autoimmune target in Heymann nephritis is a glycoprotein with homology to the LDL receptor.
        Science. 1989; 244: 1163-1165
        • Kerjaschki D.
        • Farquhar M.G.
        The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border.
        Proc Natl Acad Sci U S A. 1982; 79: 5557-5581
        • Kerjaschki D.
        • Farquhar M.G.
        Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats.
        J Exp Med. 1983; 157: 667-686
        • Kerjaschki D.
        • Miettinen A.
        • Farquhar M.G.
        Initial events in the formation of immune deposits in passive Heymann nephritis.
        J Exp Med. 1987; 166: 109-128
        • Debiec H.
        • Guigonis V.
        • Mougenot B.
        • et al.
        Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies.
        N Engl J Med. 2002; 346: 2053-2060
        • Ayalon R.
        • Beck Jr., L.H.
        Membranous nephropathy: not just a disease for adults.
        Pediatr Nephrol. 2015; 30: 31-39
        • Beck Jr., L.H.
        • Bonegio R.G.
        • Lambeau G.
        • et al.
        M-Type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.
        N Engl J Med. 2009; 361: 11-21
        • Debiec H.
        • Ronco P.
        PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy.
        N Engl J Med. 2011; 364: 689-690
        • Hoxha E.
        • Kneissler U.
        • Stege G.
        • et al.
        Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy.
        Kidney Int. 2012; 82: 797-804
        • Tomas N.M.
        • Beck Jr., L.H.
        • Meyer-Schwesinger C.
        • et al.
        Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.
        N Engl J Med. 2014; 371: 2277-2287
        • Godel M.
        • Grahammer F.
        • Huber T.B.
        Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.
        N Engl J Med. 2015; 372: 1073
        • Iwakura T.
        • Ohashi N.
        • Kato A.
        • Baba S.
        • Yasuda H.
        Prevalence of enhanced granular expression of thrombospondin type-1 domain-containing 7A in the glomeruli of Japanese patients with idiopathic membranous nephropathy.
        PLoS One. 2015; 10: e0138841
        • Hofstra J.M.
        • Fervenza F.C.
        • Wetzels J.F.
        Treatment of idiopathic membranous nephropathy.
        Nat Rev Nephrol. 2013; 9: 443-458
        • Ponticelli C.
        • Glassock R.J.
        Glomerular diseases: membranous nephropathy–a modern view.
        Clin J Am Soc Nephrol. 2014; 9: 609-616
        • Salant D.J.
        • Cattran D.C.
        Membranous nephropathy.
        in: Johnson R.J. Feehally J. Floege J. Comprehensive Clinical Nephrology. 5th ed. Elsevier, Philadelphia, PA2014: 239-252
        • Hofstra J.M.
        • Beck Jr., L.H.
        • Beck D.M.
        • Wetzels J.F.
        • Salant D.J.
        Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy.
        Clin J Am Soc Nephrol. 2011; 6: 1286-1291
        • Hoxha E.
        • Harendza S.
        • Pinnschmidt H.O.
        • et al.
        Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy.
        Nephrol Dial Transplant. 2015; 30: 1862-1869
        • Akiyama S.
        • Akiyama M.
        • Imai E.
        • Ozaki T.
        • Matsuo S.
        • Maruyama S.
        Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy.
        Clin Exp Nephrol. 2015; 19: 653-660
        • Schlumberger W.
        • Hornig N.
        • Lange S.
        • et al.
        Differential diagnosis of membranous nephropathy with autoantibodies to phospholipase A2 receptor 1.
        Autoimmun Rev. 2014; 13: 108-113
        • Dahnrich C.
        • Komorowski L.
        • Probst C.
        • et al.
        Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy.
        Clin Chim Acta. 2013; 421: 213-218
        • Kanigicherla D.
        • Gummadova J.
        • McKenzie E.A.
        • et al.
        Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.
        Kidney Int. 2013; 83: 940-948
        • Behnert A.
        • Schiffer M.
        • Muller-Deile J.
        • Beck Jr., L.H.
        • Mahler M.
        • Fritzler M.J.
        Antiphospholipase A(2) receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy.
        J Immunol Res. 2014; 2014: 143274
        • Ronco P.
        • Debiec H.
        Pathogenesis of membranous nephropathy: recent advances and future challenges.
        Nat Rev Nephrol. 2012; 8: 203-213
        • Huang X.
        • Qin W.
        • Zhang M.
        • Zheng C.
        • Zeng C.
        • Liu Z.
        Detection of anti-PLA2R autoantibodies and IgG subclasses in post-allogeneic hematopoietic stem cell transplantation membranous nephropathy.
        Am J Med Sci. 2013; 346: 32-37
        • Qin W.
        • Beck Jr., L.H.
        • Zeng C.
        • et al.
        Anti-phospholipase A2 receptor antibody in membranous nephropathy.
        J Am Soc Nephrol. 2011; 22: 1137-1143
        • Dauvergne M.
        • Moktefi A.
        • Rabant M.
        • et al.
        Membranous nephropathy associated with immunological disorder-related liver disease: a retrospective study of 10 cases.
        Medicine (Baltimore). 2015; 94: e1243
        • Xie Q.
        • Li Y.
        • Xue J.
        • et al.
        Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy.
        Am J Nephrol. 2015; 41: 345-353
        • Hoxha E.
        • Harendza S.
        • Zahner G.
        • et al.
        An immunofluorescence test for phospholipase-A(2)-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis.
        Nephrol Dial Transplant. 2011; 26: 2526-2532
        • Svobodova B.
        • Honsova E.
        • Ronco P.
        • Tesar V.
        • Debiec H.
        Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy.
        Nephrol Dial Transplant. 2013; 28: 1839-1844
        • Hofstra J.M.
        • Wetzels J.F.
        Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues.
        J Am Soc Nephrol. 2014; 25: 1137-1139
        • Larsen C.P.
        • Messias N.C.
        • Silva F.G.
        • Messias E.
        • Walker P.D.
        Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies.
        Mod Pathol. 2013; 26: 709-715
        • Fresquet M.
        • Jowitt T.A.
        • Gummadova J.
        • et al.
        Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy.
        J Am Soc Nephrol. 2015; 26: 302-313
        • van de Logt A.E.
        • Hofstra J.M.
        • Wetzels J.F.
        Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up.
        Kidney Int. 2015; 87: 1263-1264
        • Ramachandran R.
        • Kumar V.
        • Nada R.
        • Jha V.
        Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy.
        Kidney Int. 2015; 88: 1198-1199
        • Timmermans S.A.
        • Ayalon R.
        • van Paassen P.
        • et al.
        Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy.
        Am J Kidney Dis. 2013; 62: 1223-1225
        • Oh Y.J.
        • Yang S.H.
        • Kim D.K.
        • Kang S.W.
        • Kim Y.S.
        Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy.
        PLoS One. 2013; 8: e62151
        • Beck Jr., L.H.
        • Fervenza F.C.
        • Beck D.M.
        • et al.
        Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.
        J Am Soc Nephrol. 2011; 22: 1543-1550
        • Hofstra J.M.
        • Debiec H.
        • Short C.D.
        • et al.
        Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.
        J Am Soc Nephrol. 2012; 23: 1735-1743
        • Hoxha E.
        • Thiele I.
        • Zahner G.
        • Panzer U.
        • Harendza S.
        • Stahl R.A.
        Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.
        J Am Soc Nephrol. 2014; 25: 1357-1366
        • Ruggenenti P.
        • Debiec H.
        • Ruggiero B.
        • et al.
        Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy.
        J Am Soc Nephrol. 2015; 26: 2545-2558
        • Beck L.H.
        • Fervenza F.C.
        • Beck D.M.
        • Bonegio R.G.B.
        • Erickson S.B.
        • Salant D.J.
        Association of anti-PLA2R antibody level with clinical response to rituximab in idiopathic membranous nephropathy.
        J Am Soc Nephrol. 2009; 20 ([abstract]): 3A-4A
        • Bech A.P.
        • Hofstra J.M.
        • Brenchley P.E.
        • Wetzels J.F.
        Association of anti-PLA(2)R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.
        Clin J Am Soc Nephrol. 2014; 9: 1386-1392
        • Seitz-Polski B.
        • Dolla G.
        • Payre C.
        • et al.
        Cross-reactivity of anti-PLA2R1 autoantibodies to rabbit and mouse PLA2R1 antigens and development of two novel ELISAs with different diagnostic performances in idiopathic membranous nephropathy.
        Biochimie. 2015; 118: 104-115
        • Hoxha E.
        • Harendza S.
        • Pinnschmidt H.
        • Panzer U.
        • Stahl R.A.
        PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system.
        PLoS One. 2014; 9: e110681
        • Hoxha E.
        • Harendza S.
        • Pinnschmidt H.
        • Panzer U.
        • Stahl R.A.
        M-Type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.
        Clin J Am Soc Nephrol. 2014; 9: 1883-1890
        • Klouda P.T.
        • Manos J.
        • Acheson E.J.
        • et al.
        Strong association between idiopathic membranous nephropathy and HLA-DRW3.
        Lancet. 1979; 2: 770-771
        • Le Petit J.C.
        • Laurent B.
        • Berthoux F.C.
        HLA-DR3 and idiopathic membranous nephritis (IMN) association.
        Tissue Antigens. 1982; 20: 227-228
        • Vaughan R.W.
        • Demaine A.G.
        • Welsh K.I.
        A DQA1 allele is strongly associated with idiopathic membranous nephropathy.
        Tissue Antigens. 1989; 34: 261-269
        • Ogahara S.
        • Naito S.
        • Abe K.
        • Michinaga I.
        • Arakawa K.
        Analysis of HLA class II genes in Japanese patients with idiopathic membranous glomerulonephritis.
        Kidney Int. 1992; 41: 175-182
        • Chevrier D.
        • Giral M.
        • Perrichot R.
        • et al.
        Idiopathic and secondary membranous nephropathy and polymorphism at TAP1 and HLA-DMA loci.
        Tissue Antigens. 1997; 50: 164-169
        • Kim S.
        • Chin H.J.
        • Na K.Y.
        • et al.
        Single nucleotide polymorphisms in the phospholipase A2 receptor gene are associated with genetic susceptibility to idiopathic membranous nephropathy.
        Nephron Clin Pract. 2011; 117: c253-c258
        • Liu Y.H.
        • Chen C.H.
        • Chen S.Y.
        • et al.
        Association of phospholipase A2 receptor 1 polymorphisms with idiopathic membranous nephropathy in Chinese patients in Taiwan.
        J Biomed Sci. 2010; 17: 81
        • Stanescu H.C.
        • Arcos-Burgos M.
        • Medlar A.
        • et al.
        Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy.
        N Engl J Med. 2011; 364: 616-626
        • Coenen M.J.
        • Hofstra J.M.
        • Debiec H.
        • et al.
        Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy.
        J Am Soc Nephrol. 2013; 24: 677-683
        • Lv J.
        • Hou W.
        • Zhou X.
        • et al.
        Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy.
        J Am Soc Nephrol. 2013; 24: 1323-1329
        • Larsen C.P.
        • Beggs M.L.
        • Walker P.D.
        • Saeed M.
        • Ambruzs J.M.
        • Messias N.C.
        Histopathologic effect of APOL1 risk alleles in PLA2R-associated membranous glomerulopathy.
        Am J Kidney Dis. 2014; 64: 161-163
        • Salant D.J.
        Genetic variants in membranous nephropathy: perhaps a perfect storm rather than a straightforward conformeropathy?.
        J Am Soc Nephrol. 2013; 24: 525-528
        • Llorca O.
        Extended and bent conformations of the mannose receptor family.
        Cell Mol Life Sci. 2008; 65: 1302-1310
        • Kao L.
        • Lam V.
        • Waldman M.
        • Glassock R.J.
        • Zhu Q.
        Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy.
        J Am Soc Nephrol. 2015; 26: 291-301
        • Beck L.H.
        • Sandor D.G.
        • Ma H.
        • Salant D.J.
        Identification of distinct dominant and subdominant humoral epitopes within PLA2R1 in primary membranous nephropathy.
        J Am Soc Nephrol. 2014; 25 ([abstract]): 17A
      1. Seitz-Polski B, Dolla G, Payré C, et al. Epitope spreading in PLA2R1 is associated with bad prognosis in membranous nephropathy [published online ahead of print November 13, 2015]. J Am Soc Nephrol. http://dx.doi.org/10.1681/ASN.2014111061.

        • Cosyns J.P.
        • Couchoud C.
        • Pouteil-Noble C.
        • Squifflet J.P.
        • Pirson Y.
        Recurrence of membranous nephropathy after renal transplantation: probability, outcome and risk factors.
        Clin Nephrol. 1998; 50: 144-153
        • Josephson M.A.
        • Spargo B.
        • Hollandsworth D.
        • Thistlethwaite J.R.
        The recurrence of recurrent membranous glomerulopathy in a renal transplant recipient: case report and literature review.
        Am J Kidney Dis. 1994; 24: 873-878
        • Floege J.
        Recurrent glomerulonephritis following renal transplantation: an update.
        Nephrol Dial Transplant. 2003; 18: 1260-1265
        • Moroni G.
        • Gallelli B.
        • Quaglini S.
        • et al.
        Long-term outcome of renal transplantation in patients with idiopathic membranous glomerulonephritis (MN).
        Nephrol Dial Transplant. 2010; 25: 3408-3415
        • Dabade T.S.
        • Grande J.P.
        • Norby S.M.
        • Fervenza F.C.
        • Cosio F.G.
        Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy study.
        Am J Transplant. 2008; 8: 1318-1322
        • El-Zoghby Z.M.
        • Grande J.P.
        • Fraile M.G.
        • Norby S.M.
        • Fervenza F.C.
        • Cosio F.G.
        Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies.
        Am J Transplant. 2009; 9: 2800-2807
        • Floege J.
        • Regele H.
        • Gesualdo L.
        • ERA-EDTA Immunonephrology Working Group
        The ERA-EDTA database on recurrent glomerulonephritis following renal transplantation.
        Nephrol Dial Transplant. 2014; 29: 15-21
        • Stahl R.
        • Hoxha E.
        • Fechner K.
        PLA2R autoantibodies and recurrent membranous nephropathy after transplantation.
        N Engl J Med. 2010; 363: 496-498
        • Debiec H.
        • Martin L.
        • Jouanneau C.
        • et al.
        Autoantibodies specific for the phospholipase A2 receptor in recurrent and de novo membranous nephropathy.
        Am J Transplant. 2011; 11: 2144-2152
        • Blosser C.D.
        • Ayalon R.
        • Nair R.
        • Thomas C.
        • Beck Jr., L.H.
        Very early recurrence of anti-phospholipase A2 receptor-positive membranous nephropathy after transplantation.
        Am J Transplant. 2012; 12: 1637-1642
        • Kattah A.
        • Ayalon R.
        • Beck Jr., L.H.
        • et al.
        Anti-phospholipase A(2) receptor antibodies in recurrent membranous nephropathy.
        Am J Transplant. 2015; 15: 1349-1359
        • Quintana L.F.
        • Blasco M.
        • Seras M.
        • et al.
        Antiphospholipase A2 receptor antibody levels predict the risk of posttransplantation recurrence of membranous nephropathy.
        Transplantation. 2015; 99: 1709-1714
        • Seitz-Polski B.
        • Payre C.
        • Ambrosetti D.
        • et al.
        Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients.
        Nephrol Dial Transplant. 2014; 29: 2334-2342
        • Andresdottir M.B.
        • Wetzels J.F.
        Increased risk of recurrence of membranous nephropathy after related donor kidney transplantation.
        Am J Transplant. 2012; 12: 265-266
        • El Kossi M.
        • Harmer A.
        • Goodwin J.
        • et al.
        De novo membranous nephropathy associated with donor-specific alloantibody.
        Clin Transplant. 2008; 22: 124-127
        • Honda K.
        • Horita S.
        • Toki D.
        • et al.
        De novo membranous nephropathy and antibody-mediated rejection in transplanted kidney.
        Clin Transplant. 2011; 25: 191-200
        • Lim B.J.
        • Kim M.S.
        • Kim Y.S.
        • Kim S.I.
        • Jeong H.J.
        C4d deposition and multilayering of peritubular capillary basement membrane in posttransplantation membranous nephropathy indicate its association with antibody-mediated injury.
        Transplant Proc. 2012; 44: 619-620
        • Ponticelli C.
        • Glassock R.J.
        De novo membranous nephropathy (MN) in kidney allografts. A peculiar form of alloimmune disease?.
        Transpl Int. 2012; 25: 1205-1210
        • Larsen C.P.
        • Walker P.D.
        Phospholipase A2 receptor (PLA2R) staining is useful in the determination of de novo versus recurrent membranous glomerulopathy.
        Transplantation. 2013; 95: 1259-1262